drugset / Trial / NCT03650348
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
Timeline
- Start
- 2018-08-21
- Primary completion
- 2022-08-11
- Completion
- 2022-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Cinrebafusp alfa | Other / unclassified | — | Intravenous |